Operationally, our Jining histopathology laboratory section is coming together nicely. Despite the challenges presented by COVID-19 measures, we have been able to meet target timelines and remain on schedule. We have retained a full laboratory team who are English speakers and have pharma biomarker service experience.


Now that our Jining team is back in the lab, equipment installation is ongoing and is on track to receive samples next month. In our IHC department, we currently have:

  • two (2) qualified and validated BenchMark ULTRAs,
  • one (1) DISCOVERY ULTRA,
  • a Tissue-Tek Prisma® Plus Automated Slide Stainer,
  • and a Tissue-Tek Film® Coverslipper from Sakura®.

Our digital pathology department is validating the 3D HISTECH Pannoramic 250 Flash III Scanner.


On March 30, our Chinese team returned back to the building to resume their set-up of our facility in Jining, China. This is a very meaningful date for us, our first laboratory in our global network to return to non-quarantine working condition. Parts of China, e.g., the city of Beijing, remain under quarantine guidelines. Our Beijing employees who are in Jining face a 2-week quarantine if they decide to return home to Beijing. We are grateful for their willingness to resume operations and we have provided accommodations for them. Our laboratory will be ready to receive specimens for IHC and flow cytometry testing in June.


At Caprion-HistoGeneX, our top priority is the health and safety of our employees, our partners and our clients. Just like you, our team follows the COVID-19 pandemic closely to ensure rapid response as the situation evolves. As we remain committed to ensuring our clients and partners can continue moving their research forward, we have taken different steps to mitigate risks and ensure our continued support around the world. Here is some information about these measures:

  • We have implemented an internal policy ensuring that our employees respect all the measures required to minimize the risk of infection and dissemination within our facilities, including social distancing and good hygiene practices, based on WHO and local recommendations
  • All employees who can do so are required to work from home
  • Access to our facilities is restricted to our employees and to suppliers whose services are absolutely required to maintain our activities
  • All non-essential business travels have been cancelled and employees returning from a trip are self-isolating at home
  • Operational teams are split through different workspace or work shifts, whenever possible to reduce risk
  • We are in close communication with our suppliers to ensure a continuous supply of all critical material and reagents.

Our management team meets daily to monitor the situation and adapt our mitigation plan to help “flatten the curve” while reducing disruptions for our clients.

All our laboratories are currently operational, and we remain committed to continuing to support our partners during these critical times and hope you and your loved ones are and will remain safe.

For any questions regarding this particular situation, please contact our This email address is being protected from spambots. You need JavaScript enabled to view it.. All other questions may be directed to This email address is being protected from spambots. You need JavaScript enabled to view it..


Martin LeBlanc
President & CEO
Caprion Biosciences-HistoGeneX

"I would also like to take this opportunity to congratulate HGX for their attitude/proactivity during the pandemic and also how EXTREMELY happy we are with the team supporting our trial."

Sr. Director, Translational Medicine, Pharma


We are pleased to bring this update to you about our Chinese laboratory. Despite the coronavirus outbreak, we are very excited by the progress we are making for this landmark facility and very much appreciate your encouragement, enthusiasm and questions. We will provide these monthly updates as we approach our go-live date of June 2020.


In early November, HistoGeneX pathologists published a paper in Nature Medicine, in collaboration with researchers from Barts Cancer Institute, Queen Mary University of London.